secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0000950170-22-019405
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY
--------------------------------------------------------------------------------

- Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.
- Core lung diagnostic testing revenue $8.9M-$9.2M, a 96-103% increase YoY.
- COVID testing revenue $1.1M-$1.3M, up 117-157% YoY; expects immaterial in Q4.
- Biopharma services revenue $0.6M-$0.7M, down 53-60% YoY due to clinical study delays.
- Cash and equivalents $15.2M as of Sep 30; expects FY2022 revenue near high end of $37.5M-$39.5M guidance range.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/0000950170-22-019405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/bdsx-20221011.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer